Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp> , Randomized, <scp>Double‐Blind</scp> , <scp>Placebo‐Controlled</scp> Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial

Published:2022-11-11 Issue:2 Volume:75 Page:242-252
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Morand Eric¹^ORCID,Pike Marilyn²,Merrill Joan T.³^ORCID,van Vollenhoven Ronald⁴,Werth Victoria P.⁵^ORCID,Hobar Coburn⁶,Delev Nikolay⁶,Shah Vaishali⁶,Sharkey Brian⁶,Wegman Thomas⁶,Catlett Ian⁶,Banerjee Subhashis⁶,Singhal Shalabh⁶

Affiliation:

1. Monash University and Department of Rheumatology Monash Health Victoria Australia

2. MedPharm Consulting, Inc. Raleigh North Carolina

3. Oklahoma Medical Research Foundation Oklahoma City

4. Amsterdam University Medical Centers Amsterdam the Netherlands

5. University of Pennsylvania and the Michael J. Crescenz VA Medical Center Philadelphia

6. Bristol Myers Squibb Princeton New Jersey

Funder

Bristol-Myers Squibb Canada

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42391

Reference37 articles.

1. Systemic lupus erythematosus

2. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus

3. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

4. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls

5. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs);Joint Bone Spine;2024-03

2. Emerging biologic therapies for systemic lupus erythematosus;Current Opinion in Rheumatology;2024-02-02

3. Vascular damage in systemic lupus erythematosus;Nature Reviews Nephrology;2024-01-03

4. Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: A case report;Journal of the European Academy of Dermatology and Venereology;2023-12-07

5. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis;Autoimmunity Reviews;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3